Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for